1-3 of 3
Arjan C. Lankester
Close
Sort by
Journal Articles

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study

Clinical Trials & Observations
Federica R. Achini-Gutzwiller, Marco W. Schilham, Erik G. J. von Asmuth, Anja M. Jansen-Hoogendijk, Cornelia M. Jol-van der Zijde, Maarten J. D. van Tol, Robbert G. M. Bredius, Tayfun Güngör, Arjan C. Lankester, Dirk Jan A. R. Moes
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4462–4474.
https://doi.org/10.1182/bloodadvances.2022009051
Published: 2023
Includes: Supplemental data
Journal Articles

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen

Clinical Trials & Observations
A. Birgitta Versluijs, Coco C. H. de Koning, Arjan C. Lankester, Stefan Nierkens, Wouter J. Kollen, Dorine Bresters, Caroline A. Lindemans, Jaap Jan Boelens, Marc Bierings
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1719–1730.
https://doi.org/10.1182/bloodadvances.2021005224
Published: 2022
Includes: Supplemental data
Journal Articles

Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis

Clinical Trials & Observations
Matthias Felber, Colin G. Steward, Karim Kentouche, Anders Fasth, Robert F. Wynn, Ulrike Zeilhofer, Veronika Haunerdinger, Benjamin Volkmer, Seraina Prader, Bernd Gruhn, Stephan Ehl, Kai Lehmberg, Daniel Müller, Andrew R. Gennery, Michael H. Albert, Fabian Hauck, Kanchan Rao, Paul Veys, Moustapha Hassan, Arjan C. Lankester, Jana Pachlopnik Schmid, Mathias M. Hauri-Hohl, Tayfun Güngör
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1998–2010.
https://doi.org/10.1182/bloodadvances.2020001748
Published: 2020
Includes: Supplemental data